What Is Wegovy? Uses, Results, Side Effects & Cost

Mechanism

How Wegovy Works

Wegovy is semaglutide — a long-acting GLP-1 receptor agonist — titrated to a 2.4 mg weekly maintenance dose, the highest semaglutide dose approved in the United States. It activates GLP-1 receptors in the pancreas, gut, and central satiety pathways in the hypothalamus and brainstem [6].

The clinical effect is reduced appetite, earlier satiety, slowed gastric emptying, and a measurable drop in cravings for highly palatable foods. Glycemic effects are present but secondary; Wegovy's primary indication is weight management, not diabetes [1].

Dosing escalates monthly — 0.25, 0.5, 1.0, 1.7, then 2.4 mg — to limit GI side effects. The full 2.4 mg dose is reached over 16–17 weeks, and the weight-loss curve typically continues for roughly a year before plateauing [2].

Clinical Evidence

Wegovy for Weight Loss: What the Research Shows

In STEP 1, adults without diabetes on Wegovy 2.4 mg lost a mean of 14.9% of body weight at 68 weeks versus 2.4% on placebo. Roughly one in three participants lost ≥20% of body weight [2].

STEP 4 showed that continuing Wegovy after a 20-week run-in led to an additional 7.9% mean weight loss, while switching to placebo caused a 6.9% regain over the same period — demonstrating that the medication's effect is dependent on continued use [2].

SELECT then established a cardiovascular benefit independent of diabetes: semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and pre-existing cardiovascular disease, leading to a 2024 FDA label expansion [4].

Candidacy

Who Is a Candidate?

Wegovy is FDA-approved for adults with BMI ≥30, or BMI ≥27 with at least one weight-related condition (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, cardiovascular disease). It is also approved for adolescents 12 and older with obesity, and for cardiovascular-event reduction in adults with overweight/obesity and established cardiovascular disease [1].

Good candidates have realistic expectations: 1–2 lb/week of loss across the first year, plateau around month 12–15, and a long-term commitment to remaining on therapy or to a structured maintenance plan if discontinuing.

Contraindications mirror Ozempic: personal or family history of medullary thyroid carcinoma, MEN2, prior serious hypersensitivity, and pregnancy. Patients with a history of pancreatitis, severe gastroparesis, active gallbladder disease, or eating disorders require careful evaluation before starting [1].

Safety

Side Effects & Safety

The most common adverse effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, abdominal pain, and reflux. These peak during titration and improve with smaller meals, hydration, and patience. Severe or persistent symptoms warrant a dose pause or physician reassessment [1].

Documented less-common risks include gallbladder disease, acute pancreatitis, acute kidney injury from dehydration, hypoglycemia (especially with concurrent insulin or sulfonylureas), diabetic retinopathy complications in patients with pre-existing retinopathy, and rare reports of suicidal ideation. The boxed warning for rodent MTC tumors and the MTC/MEN2 contraindication apply [1].

Loss of lean mass is meaningful at Wegovy doses because the weight loss is larger. Without adequate dietary protein and resistance training, 25–40% of weight lost can be lean mass. A physician-led program builds this in from week one — it is the difference between weight loss and a high-quality body-composition change.

Compare

Wegovy vs. Ozempic vs. Mounjaro

All three are once-weekly subcutaneous injections, but the indications and weight-loss magnitudes differ:

• ·Wegovy (semaglutide 2.4 mg): FDA-approved for chronic weight management; ~14.9% mean weight loss at 68 weeks [2].
• ·Ozempic (semaglutide, up to 2 mg): FDA-approved for type 2 diabetes; ~6–10% weight loss is typical at the 2 mg dose.
• ·Zepbound (tirzepatide, up to 15 mg): FDA-approved for chronic weight management; ~20–22.5% mean weight loss in SURMOUNT-1, and superior to semaglutide in the SURMOUNT-5 head-to-head trial [3].

Full comparison: /hautemd/compare/ozempic-vs-mounjaro-vs-zepbound/.

Cost

How Much Does Wegovy Cost?

Wegovy's list price is approximately $1,349/month (Novo Nordisk, June 2026). Commercial insurance coverage for obesity treatment has expanded but remains inconsistent; Medicare Part D does not currently cover Wegovy for weight loss, only for the cardiovascular-event-reduction indication after the 2024 label expansion.

Novo Nordisk's direct-pay NovoCare Pharmacy program offers self-pay options that change frequently. Eligible commercially insured patients may pay as little as $25/month via the Wegovy Savings Card; cash-pay pricing without insurance is generally $499/month or higher depending on dose and program eligibility. Re-verify quarterly.

Haute MD Standard

Why Physician-Guided Wegovy Treatment Matters

Wegovy is the highest-dose semaglutide on the market, which means the upside and the side-effect profile are both larger. A 30-second online questionnaire cannot substitute for baseline labs, body-composition assessment, hormone panels where indicated, and a titration plan responsive to how you actually feel.

A Haute MD–standard program runs Wegovy alongside protein-targeted nutrition, structured resistance training, and quarterly DEXA or bioimpedance — because the goal is fat loss with lean-mass preservation, not just a smaller number on the scale. The maintenance phase — what happens after month 14 — is planned in advance, not improvised when the prescription runs out.